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Abstract: Our aim was to determine the appropriate salvage regi-
men for Chinese non-small cell lung cancer (NSCLC) patients who
failed previous chemotherapy. We retrospectively analyzed data
from our seven clinical trials, including single-agent gemcitabine,
gefitinib, docetaxel with a different schedule, vinorelbine plus cis-
platin, vinorelbine plus gemcitabine, docetaxel plus gemcitabine,
and docetaxel plus ifosfamide, with a total of 342 cases (including
314 patients, of which 28 entered two different trials due to different
salvage line settings), and compared these data with those of other
studies, addressing the efficacy and toxicity of salvage therapy in
patients who failed previous chemotherapy to analyze choosing of
an appropriate salvage regimen. Of the 342 cases receiving salvage
treatment, 71.1% were in second-line treatment, and 28.9% in
third-line or later treatment. The response rate to our salvage therapy
ranged widely, from 6.1% to 36.1%. Median survival was between
5.7 and 8.4 months when different salvage chemotherapy regimens
were used, whereas it was 9.3 months in those who received
gefitinib treatment. Similarly, 1-year survival ranged between 19.7%
and 40% in a chemotherapy setting, and 40.8% for gefitinib treat-
ment. Those who received gefitinib had better toxicity profiles than
those who received other regimens. Febrile neutropenia occurred in
19 patients who received a chemotherapy agent (6.2%), and four
patients died despite granulocyte colony-stimulating factor and an-
tibiotic treatment. Grade 3 or 4 interstitial pneumonitis occurred in
14 of 247 patients (5.7%) who received docetaxel with/without
another agent, and 10 patients died. Grade 3 interstitial pneumonitis
occurred in one patient who received gefitinib treatment and recov-
ered. In conclusion, both chemotherapeutic agents, such as docetaxel
alone or gemcitabine plus vinorelbine, and gefitinib, are probably
appropriate salvage regimens for Chinese NSCLC patients who have
failed previous chemotherapy. However, gefitinib has a better safety
profile and probably better survival than the chemotherapeutic
agents and would be an appropriate alternative choice for salvage
chemotherapy, even in a second-line setting for Chinese patients.
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Because the benefit of first-line chemotherapy with plati-num-based new agents (such as taxanes or gemcitabine)
for non-small cell lung cancer (NSCLC) has been docu-
mented to be better than that of second-generation chemo-
therapy (such as etoposide or vindesine), the use of new
chemotherapeutic agents in a salvage setting for the patient
who has failed primary chemotherapy has been under active
investigation in recent years. Docetaxel was the first new
anticancer drug to demonstrate a survival advantage in sec-
ond-line chemotherapy for NSCLC, with a prolongation of
patient survival in phase III randomized trials comparing
docetaxel with vinorelbine or ifosfamide, or with the best
supportive care, for NSCLC patients who have failed previ-
ous chemotherapy1,2; thus, it has been recommended as the
second-line treatment of NSCLC.3 Later, pemetrexed showed
similar activity, but with less toxicity, when compared with
docetaxel treatment in a phase III randomized trial of NSCLC
patients previously treated with chemotherapy.3,4 In addition,
epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), a new class of anticancer agent, have been
found to be effective since 2003 in the salvage treatment of
NSCLC patients who failed previous chemotherapy; these
salvage treatments included erlotinib in second-line or third-
line treatment and gefitinib for patients after failure with both
platinum-based and docetaxel chemotherapies.3,5–7
In addition to docetaxel, pemetrexed, and EGFR-TKIs,
which have been documented to be effective in salvage
therapy for NSCLC patients who have failed previous che-
motherapy, many other agents or combination regimens have
been evaluated for the treatment of this patient population. In
the present study, we used data from our clinical trials to find
the optimal therapy options for Chinese NSCLC patients who
failed previous chemotherapy.
PATIENTS AND METHODS
We retrospectively reviewed and analyzed seven clin-
ical trials using new anticancer drugs against advanced-stage
NSCLC patients who failed previous chemotherapy, which
we undertook between 1998 and 2004. A total of 342 cases
were enrolled, including 314 patients, of which 28 entered
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two different trials due to different salvage line settings.
These studies were conducted according to the existing rules
for good clinical practice, and the protocols were approved by
the local ethics committee. Informed consent was signed by
all patients. The seven trials included a single-agent gemcit-
abine study (20 patients),8 a vinorelbine plus cisplatin study
(22 patients),9 a vinorelbine plus gemcitabine study (17
patients),10 a docetaxel plus gemcitabine study (36 pa-
tients),11 a docetaxel plus ifosfamide study (50 patients),12 a
docetaxel with three different schedules study (161 pa-
tients),13 and a single-agent gefitinib study (36 patients).14
The clinical characteristics, response rate, toxicity pro-
files, and survival were compared between the different
treatment regimens. The response rate and survival were both
analyzed with an intention-to-treat principle. Drug-related
toxicity and types of response were assessed and recorded
according to established Eastern Cooperative Oncology
Group criteria.15 Overall survival and time-to-disease pro-
gression were analyzed using the Kaplan-Meier estimation
method and log-rank test. Time-to-disease progression was
calculated from the date of initiation of salvage treatment to
the date of disease progression or death. Progression-free
survival was considered censored if disease progression had
not occurred before the end of February of 2006. Survival
time was measured from the date of initiation of salvage
treatment to the date of death. If death had not occurred
before the end of February of 2006, survival time was
considered censored. Of the 28 patients who entered two
different protocols, survival time was counted only once for
the later treatment (survival time for the earlier treatment
undergone by these patients was excluded from analysis),
when the survival time of second-line treatment was com-
pared with the third-line or later treatment and when gefitinib
treatment was compared with other treatments. Kruskal-
Wallis nonparametric tests for multiple independent samples
were used for comparisons of grade 3 or 4 toxicity inci-
dences, including leukopenia, neutropenia, thrombocytope-
nia, anemia, vomiting, myalgia, fatigue, diarrhea, constipa-
tion, mucositis, and pneumonitis between the different
treatment regimens. For the statistical analysis of the above-
mentioned grade 3 or 4 toxicity incidences between the two
different treatment regimens, the Mann-Whitney test was
used. The Pearson correlation test was performed to deter-
mine whether there existed a significant correlation between
treatment response rate and time to disease progression,
median survival, or 1-year survival.
RESULTS
These seven studies, including 9 different regimens or
schedules, were performed from 1998 to 2004.8–14 A total of
342 cases received salvage chemotherapy in these seven
studies, including 314 patients, of which 28 entered two
different trials due to different salvage line settings (including
24 patients who entered gefitinib treatment later and another
four who entered gemcitabine-alone treatment). The patients’
clinical characteristics are summarized in Table 1. Patient age
distributions overlapped in these studies. Females accounted
for 23% to 55% of the study population for the different
regimens. The majority of patients had a performance status
of 2. Patients who had a performance status of 3 or 4 could
also enter the trial and receive gefitinib treatment or gemcit-
abine plus vinorelbine treatment. The majority of the salvage
treatment in the present study was second-line (n  243,
71.1%), except the single-agent gemcitabine and gefitinib
treatments, which were mainly third-line or later (Table 1).
Docetaxel plus gemcitabine treatment was used equally in
second- and third-line treatment. The dose and schedules of
agents given are shown in Table 2. The response rate was
10% in the docetaxel 75 mg treatment (6.1%) and the
vinorelbine plus cisplatin treatment (9.5%), whereas it was
30% in the gefitinib treatment (33.3%), docetaxel plus
gemcitabine treatment (36.1%), and gemcitabine plus vi-
norelbine treatment (31.3%) (Table 2).
Median survival ranged from 5.7 to 9.3 months, and the
best data was obtained from those receiving daily gefitinib
treatment. The 1-year survival rate was between 26.1% and
40.8%, but those who received vinorelbine plus cisplatin had
a lower 1-year survival rate. Response rates were not corre-
lated with the patients’ 1-year survival rates (p  0.197),
TABLE 1. Clinical Characteristics of Studies for Salvage Therapy in Non-Small Cell Lung Cancer
Trial Patient no.
Mean age,
y (range) Male/female, %
Performance
status 0/1/2/3/4, %
Present treatment
as second-/third-line, %
Single agent
Gemcitabine 20 61 (45-75) 45/55 0/25/75/0/0 15/85
Docetaxel
35 mg 64 65 (23-82) 69/31 3/38/59/0/0 92/8
40 mg 64 63 (35-85) 66/34 0/44/56/0/0 89/11
75 mg 33 64 (34-83) 70/30 0/39/61/0/0/ 91/9
Gefitinib 36 62 (35-82) 56/44 0/25/58/14/3 28/72
Double agent
Docetaxel  ifosfamide 50 61 (38-79) 56/44 0/12/88/0/0 72/28
Docetaxel  gemcitabine 36 63 (43-85) 78/22 0/11/89/0/0 50/50
Vinorelbine  gemcitabine 17 66 (42-82) 76/24 0/6/88/6/0 76/24
Vinorelbine  cisplatin 22 70 (46-79) 77/23 0/0/100/0/0 77/23
Chen et al. Journal of Thoracic Oncology • Volume 1, Number 6, July 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer546
median time to disease progression (p  0.118), or median
survival time (p  0.482).
The overall median survival of all 314 patients was 7.4
months (1-year survival rate, 28.3%). Median survival for
patients who received their regimen as second-line treatment
(n  224, after excluding those patients who entered later-
line treatment) was 7.6 months, and for those who received
their regimen as third-line or later (n 90), it was 5.7 months
(p  0.006). The 1-year survival rates were 30.4% and
23.1%, respectively. There was no significant survival differ-
ence between groups of patients who received different treat-
ment regimens (p  0.6241). The median survival of patients
receiving gefitinib treatment (n  36) was 9.3 months, which
was insignificantly better than that of other treatments (n 
278, median 7.2 months, p  0.3945). Median survival of
those patients who received gefitinib as second-line treatment
was 9.2 months (n  10), which was insignificantly better
than that of other second-line treatments (n  214, median
7.6 months, p  0.322). Median survival of those patients
who received gefitinib as third-line or later treatment was 9.3
months (n  26), which was also insignificantly better than
that of other third-line or later treatments (n 64, median 5.4
months, p  0.0737).
Kruskal-Wallis nonparametric tests for comparisons of
incidence of grade 3 or 4 toxicity among different treatment
regimens showed there was a significant difference in leuko-
penia (p  0.001), neutropenia (p  0.001), thrombocytope-
nia (p  0.001), and fatigue (p  0.04). There was no
difference in anemia (p  0.199), vomiting (p  0.713),
myalgia (p  0.825), diarrhea (p  0.644), constipation (p 
0.853), mucositis (p  0.747), and pneumonitis (p  0.726),
among the different treatment regimens. The Mann-Whitney
TABLE 3. Hematologic Toxicities of Salvage Therapy in Non-small Cell Lung Cancer
Trial
Grade 3 or 4 toxicity, % per patients
Febrile neutropenia,
no. of patientsLeukopenia Neutropenia Thrombocytopenia Anemia
Single agent
Gemcitabine 10.0 10.0 15.0 5.0 0
Docetaxel
35 mg 14.1 14.1 3.1 3.1 1
40 mg 18.8 17.2 1.6 7.9 3 (2 died)
75 mg 45.5 75.8 0 12.1 4 (2 died)
Gefitinib 0 0 0 0 0
Double agent
Docetaxel  ifosfamide 68.0 80.0 0 4.0 7
Docetaxel  gemcitabine 19.5 25 16.7 13.9 2
Vinorelbine  gemcitabine 35.3 52.9 17.6 11.8 1
Vinorelbine  cisplatin 22.7 40.9 0 13.6 1
Febrile neutropenia occurred in 19 of 342 patients, and four patients died despite granulocyte colony–stimulating factor and antibiotic treatment.
TABLE 2. Efficacy of Salvage Therapy in Non-small Cell Lung Cancer
Trial Schedule
Response, %
(95% CI)
Median time to
progression (mo)
Median
survival (mo)
1-y survival
(%)
Single agent
Gemcitabine 1200 mg/m2 d 1, 8, 15, q 4 wk 12.5 (0–28.7) 2.1 7.5 40
Docetaxel
35 mg 35 mg/m2 d 1, 8, 15, q 4 wk 17.2 (8–26.4) 4.2 8.4 33.4
40 mg 40 mg/m2 d 1, 8, q 3 wk 10.9 (3.3–18.5) 3.5 7.4 35
75 mg 75 mg/m2 d 1 q 3 wk 6.1 (0–14.3) 2.8 7.8 30.3
Gefitinib 250 mg/d 33.3 (17.9–48.7) 4.7 9.3 40.8
Double agent
Docetaxel  ifosfamide D 60 mg/m2  I 3 g/m2 d 1 q 3
wk
10 (1.7–18.3) 5 8.2 26.1
Docetaxel  gemcitabine D 30 mg/m2  G 800 mg/m2 d
1, 8 q 3 wk
36.1 (20.3–51.9) 3.8 5.7 33.3
Vinorelbine  gemcitabine V 20 mg/m2  G 800 mg/m2 d
1, 8, 15 q 4 wk
31.3 (8.6–64) 4.6 8.3 34.3
Vinorelbine  cisplatin V 20 mg/m2 d 1, 8, 15  C 50
mg/m2 d 1 q 4 wk
9.5 (0–22) 3.7 7.6 19.7
D, docetaxel; I, ifosfamide; G, gemcitabine; V, vinorelbine; C, cisplatin; q, every.
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test was used to detect whether there existed significant
differences in leukopenia, neutropenia, thrombocytopenia,
and fatigue between any two of the treatment regimens, with
the results given in the following paragraphs.
Docetaxel plus ifosfamide significantly induced more
frequent grade 3 or 4 leukopenia than other regimens. Ge-
fitinib induced no leukopenia (Table 3, Fig. 1). The degree of
grade 3 or 4 neutropenia was similar to that of leukopenia,
with the most frequent occurrence in docetaxel plus ifosf-
amide regimens. Gefitinib was least toxic, followed by gem-
citabine (Table 3). In contrast to leukopenia and neutropenia,
which were induced more frequently with the docetaxel-
containing regimens, severe thrombocytopenia occurred
more frequently in gemcitabine-containing regimens. Other
regimens induced less severe thrombocytopenia, especially
gefitinib, with which no thrombocytopenia occurred (Table 3,
Fig. 1).
Docetaxel 40 mg and vinorelbine plus cisplatin induced
more frequent severe fatigue than the other regimens. Patients
who received gefitinib treatment reported no severe fatigue
(Table 4, Fig. 1).
The average costs of these salvage treatments are
shown in Table 5. Total costs per cycle, including the che-
motherapy drug fee, pharmacy fee, nursing fee, doctor fee,
administrative fee, and outpatient clinic fee, were highest
with docetaxel 35 mg treatment (US$2890) and lowest with
vinorelbine plus cisplatin treatment (US$1160). Total costs
per week during the treatment were highest with docetaxel
plus gemcitabine treatment (US$754) and lowest with vi-
norelbine plus cisplatin treatment (US$290).
DISCUSSION
Docetaxel 75 mg/m2 intravenous infusion every 3
weeks was the first effective regimen recommended for use in
salvage chemotherapy for those who failed previous first-line
chemotherapy.1–3 Although the docetaxel response rate was
only 6% to 7% in these phase III randomized trials, 1-year
survival was 32% to 37% in those patients who received
docetaxel 75 mg/m2 treatment every 3 weeks.1,2 Years later,
pemetrexed was found to have similar activity (the response
rate was 9.1% and 8.8% for pemetrexed and docetaxel,
respectively; the 1-year survival rate for both was 29.7%), but
lower toxicity profiles in another phase III randomized trial.4
Other chemotherapeutic agents or combination regimens that
had been used in salvage chemotherapy were usually tested in
only phase II studies and showed little activity or activity that
was similar to that of docetaxel every-3-weeks treatment.8,14
In contrast, the significant adverse effects of gemcitabine that
have an impact on the patient’s quality of life or require the
discontinuance of treatment have been reported to be less
than with other new single chemotherapeutic agents or com-
binations of agents.16–18 Gemcitabine probably also has ac-
tivity in the second-line treatment of NSCLC, with a single-
drug response rate ranging from 6% to 20.6% reported in
phase II studies.8,16,17
Fatigue was more marked in patients who received
docetaxel treatment or vinorelbine plus cisplatin treatment
(Table 4, Fig. 1). Docetaxel had the side effects of asthenia or
fatigue, and changing docetaxel from an every-3-weeks
schedule to a weekly schedule did not significantly improve
these side effects in our study. However, when the docetaxel
schedule was changed to 35 mg/m2 days 1, 8, and 15 every 4
weeks, the fatigue sensation decreased; this was also true
with combination docetaxel plus gemcitabine, in which the
docetaxel dose intensity was less and a weekly schedule was
used. Interestingly, a severe fatigue sensation also occurred
more frequently in those who received vinorelbine plus cis-
platin. Most of the patients who received a cisplatin-based
regimen in a second-line setting had had a nonplatinum
first-line treatment with little toxicity. When they received a
cisplatin-based regimen in a second-line setting, they felt
FIGURE 1. Percentage of grade 3 or 4 leukopenia (A),
thrombocytopenia (B), and fatigue (C) per patient in differ-
ent treatment regimens. A: Docetaxel plus ifosfamide was
significantly more toxic than all the other regimens (p 
0.001,  0.001,  0.001, 0.042,  0.001,  0.001, 0.018,
 0.001, respectively). B: Gemcitabine-containing regimens,
such as single-agent gemcitabine, docetaxel plus gemcitab-
ine, and vinorelbine plus gemcitabine, induced significantly
more severe thrombocytopenia than other regimens. C: Do-
cetaxel 40 mg/m2 and vinorelbine plus cisplatin induced
more frequent severe fatigue than other regimens. Gem,
gemcitabine; D35, docetaxel 35 mg/m2 weekly schedule;
D40, docetaxel 40 mg/m2 weekly schedule; D75, docetaxel
75/m2 every 3 weeks schedule; Gef, gefitinib; DI, do-
cetaxel plus ifosfamide; DG, docetaxel plus gemcitabine;
VG, vinorelbine plus gemcitabine; VC, vinorelbine plus
cisplatin.
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more fatigue, and in addition to the drug side effects, they
needed to call on the outpatient clinic twice and were admit-
ted once for hydration and for drug infusion every 4 weeks.
Ten of 247 (4%) patients who received docetaxel alone or in
combination died of chemotherapy-induced pneumonitis (Ta-
ble 4). Docetaxel-induced pneumonitis is an issue needing
further study to prevent its occurrence and decrease its impact
on patient survival.
Methods used to improve the effectiveness of salvage
chemotherapy include the addition of a second agent with
docetaxel, combination usage of two effective first-line reg-
imens, or changing docetaxel from an every 3-weeks-sched-
ule to a weekly schedule, just as we had done before.8–13
Another oral-form chemotherapeutic agent, topotecan, was
found to be no better than docetaxel treatment in a recently
published phase III randomized trial (with 829 patients en-
rolled) and had an inferior survival time (median survival, 6.5
versus 7.2 months, 1-year survival: 25.1% versus 28.7%) and
more myelotoxicities.19 Thus, not all new drugs or new
schedules of treatment produced better results than standard
docetaxel treatment.
In addition to the chemotherapeutic agents, EGFR-
TKIs, such as gefitinib and erlotinib, were also found to be
effective for second- or third-line treatment in patients who
failed previous chemotherapy.3,5–7 Erlotinib was documented
to effectively prolong patient survival compared to the best
supportive care in a BR.21 randomized phase III study,5
whereas gefitinib failed to document a survival benefit in the
ISEL (Iressa Survival Evaluation in Lung Cancer) study.20
However, gefitinib was found to prolong the survival of East
Asian patients compared to the best supportive care in a
subset analysis of the ISEL study. In our studies, no obvious
grade 3 or 4 side effect occurred in patients who received
gefitinib treatment compared to the many side effects induced
by chemotherapeutic agents. Thus, gefitinib had the best
safety profile of these salvage regimens.
The 1-year survival rate of salvage chemotherapies in
our study was similar to those of randomized docetaxel
studies or a docetaxel versus pemetrexed study, whereas the
response rates were higher in ours.1,2,4 The 1-year survival
rate of gefitinib treatment was even better in our patients
(40.8%) if we compared ours with these docetaxel random-
ized studies (29.7%–37%). The 1-year survival rate of our
patients who received gefitinib was also better than those in
a randomized study of patients who received EGFR-TKIs,
including gefitinib and erlotinib.5,20 It is well-known that East
Asians have a better response to EGFR-TKIs, as in our study.
The major weaknesses of the present study are that it
was retrospective in nature, and different clinical settings and
patient populations were used in the different trials. It would
have been better and more informative if we had performed
this study in a prospective, randomized fashion. However, it
would be very difficult to randomize patients into so many
arms at the same time.
TABLE 4. Nonhematologic Toxicities of Salvage Therapy in Non-small Cell Lung Cancer
Trial
Grade 3 or 4 toxicity, % per patients
Vomiting Myalgia Fatigue/asthenia Diarrhea Constipation Mucositis Pneumonitis
Single agent
Gemcitabine 0 0 0 0 0 0 0
Docetaxel
35 1.6 0 9.4 1.6 1.6 1.6 4.7
40 4.7 1.6 18.8 4.7 1.6 3.1 7.9
75 3.0 0 12.1 6.1 3.0 0 3.0
Gefitinib 0 0 0 0 0 0 2.8
Double agent
Docetaxel  ifosfamide 2.0 0 12.0 2.0 0 0 6.0
Docetaxel  gemcitabine 0 0 2.8 2.8 0 2.8 5.6
Vinorelbine  gemcitabine 0 0 5.9 0 0 0 0
Vinorelbine  cisplatin 9.1 0 18.2 0 0 0 0
Other toxicities included one grade 3 peripheral neuropathy in vinorelbine  gemcitabine. In addition, two patients in docetaxel  ifosfamide, two patients in docetaxel 
gemcitabine, two patients in docetaxel 35 mg, and four patients in docetaxel 40 mg died of interstitial pneumonitis.
TABLE 5. Average Costs of Salvage Chemotherapy in Non-
small Cell Lung Cancera
Cost per cycle Cost per week
Single agent
Gemcitabine 1803 451
Docetaxel
35 mg 2890 723
40 mg 1927 642
75 mg 1785 595
Gefitinib 2075 519
Double agent
Docetaxel  ifosfamide 2101 700
Docetaxel  gemcitabine 2262 754
Vinorelbine  gemcitabine 1931 483
Vinorelbine  cisplatin 1160 290
a Average costs, in U.S. dollars, for a patient with a body surface area of 1.8 m2,
including chemotherapy drug fee, pharmacy fee, nursing fee, doctor fee, administrative
fee, and outpatient clinic fee.
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In conclusion, docetaxel alone or gemcitabine plus
vinorelbine are effective and relatively safe regimens for
salvage chemotherapy for NSCLC. However, the toxicity
profile of gefitinib was better than those of the chemothera-
peutic regimens used in this retrospective study and, thus,
would be an appropriate alternative choice for salvage che-
motherapy, even in a second-line setting for Chinese patients.
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